Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sanofi, Enjaymo and Recordati
In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo
As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating $825 million upfront—plus another $250 million in potential commercial milestones—to get its hands on the global rights to Sanofi’s rare disease biologic Enjaymo.
Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo
Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment specifically targeting cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.
Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional commercial milestone payments of up to $250 million.
Sanofi Offloads Rare Autoimmune Drug to Recordati in Potential $1B Deal
Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights to a biologic for the treatment of cold agglutinin disease, with milestone payments of up to $250 million.
Sanofi’s rare disease drug finds yet another home
Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.
Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln
Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million, sending both stocks up in early trade.
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE
Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic
Recordati shares jump on deal with Sanofi for Enjaymo rights
Recordati 's (BIT: RECI) shares jumped on Friday following its deal with Sanofi (NASDAQ: SNY) to buy the global rights to Enjaymo (sutimlimab), a first-in-class b
Recordati buys rights to rare immune disorder drug from Sanofi for $825 million
(Reuters) -Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million,
MedCity News
4d
Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M
Sanofi
’s
Enjaymo
, the only approved drug therapy for a rare and debilitating blood disorder, is being acquired by Recordati in a deal that helps the Italian company build its rare disease ...
4d
on MSN
Sanofi inks $1B deal to sell autoimmune disorder therapy
French pharma giant Sanofi (NASDAQ:SNY) has agreed to sell global rights linked to Enjaymo, an FDA-approved treatment for an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
North Dakota wildfires
To campaign for Harris
Kemp suspends GA mayor
Medical copter crash kills 3
Sex abuse case dismissed
Human life expectancy study
Tickets to climb to $5
Harris on '60 Minutes'
Richest female musician
Ordered to open app store
States sue TikTok
King named grand marshal
Former aide charged
Win Nobel Prize in physics
Intel defensive briefings rise
Athlete payments approval
Settles latest civil lawsuit
NC voting rule changes
To replace lead water pipes
US antitrust case advances
Targeted by a cyberattack
Grammy-winning singer dies
Israel expands offensive
Hamas backers sanctioned
Hears ghost gun rule case
US overdose deaths drop
Hera mission launched
SCOTUS denies appeal
Liquidation plan approved
Florida orders evacuations
Feedback